Navigation Links
AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
Date:8/26/2008

What:

The AACR Molecular Diagnostics in Cancer Therapeutics Development Meeting features the latest findings in laboratory, translational and clinical cancer research. This year's meeting focuses on new biologic markers and imaging methods.

To help you take advantage of the meeting's scientific abstracts and related activities, the program schedule and related abstracts will be available online at: www.aacr.org on September 22, 2008. The press releases will be available to subscribing reporters on September 15 via Newswise and Eurekalert.

Nearly 100 abstracts will be presented at the meeting, complementing an outstanding program of scientific and educational events. The AACR Molecular Diagnostics in Cancer Therapeutics Meeting attracts world leaders in cancer research, including clinical oncologists, basic scientists and translational researchers.

Highlights:

  • Angiogenic factors that increase risk for breast cancer
  • Genetic markers for glioblastoma survival
  • New data on nanotechnology as a cost effective diagnostic method
  • More accurate tools for diagnosing myeloproliferative neoplasia
  • Late-breaking data on multispectral imaging and its utility
  • How the Epstein Barr virus predicts outcome in nasopharyngeal carcinoma

When:

September 22-25, 2008

Where:

Marriott Philadelphia Downtown
Philadelphia, PA

AACR Press Room:

Location: Room 305, Marriott
Hours: 8:00 a.m. to 6:00 p.m. ET
Phone: (215)-440-9300
Fax: (215)-440-9313
E-mail: emma.obrien@aacr.org

Hotel Accommodations:

Register for housing online at:
http://www.aacr.org/page14413.aspx
(Deadline for AACR housing block at the Marriott Hotel is Aug.29, 2
'/>"/>

Contact: Emma OBrien
emma.obrien@aacr.org
267-646-0613
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Smithsonian hosts tropical extinction debate in Panama
2. Syracuse University scientists discover how some bacteria may steal iron from their human hosts
3. Monarch butterflies help explain why parasites harm hosts
4. UTSA hosts North American Energy Summit May 1-2
5. Rockefeller University hosts 2-day evolution symposium, May 1-2, 2008
6. Brown hosts regional bioengineering conference
7. NIH hosts event to launch Council of Science Editors global theme issue
8. UD hosts conference on knowledge-based partnerships Nov. 2
9. Rice lab finds molecular clues to Wilson disease
10. Caltech researchers awarded $10M for molecular programming project
11. Newly discovered molecular switch helps decide cell type in early embryo development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... The microscopic phytoplankton Aureococcus anophagefferens , which causes ... to be a fierce competitor. In the first ... found that Aureococcus , unique gene complement allows ... human-modified ecosystems, which could help explain the global increases ...
... pathways that are mutated in many forms of cancer, ... disease including hypertrophic cardiomyopathy (HCM), a thickening of ... sudden death in children and young adults , have ... in the lab. In two separate but ...
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
Cached Biology News:First harmful algal bloom species genome sequenced 2First harmful algal bloom species genome sequenced 3Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , NATICK, Mass., Sept. 14 Boston ... that it has entered into a co-marketing agreement with ... testing solutions for urinary incontinence. Bladder Health Network ... supplies and results analysis, helping to ensure that physicians ...
... 14 Health Robotics today reported,that Dr M Group has ... of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, Vietnam, and ... on 2 companies in the field of I.V.,Robotics, the doubts ... announced multi-year delays in bringing their robot to first,hospital,s use], ...
... , , , ... announced that the results of a comprehensive review of safety data from ... Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, ... risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 2Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 3Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 5Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 6Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 7Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 8
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: